

**American College of Radiology  
ACR Appropriateness Criteria®**

**Clinical Condition:** Radiographically Detected Solitary Pulmonary Nodule

**Variant 1:** Solid nodule  $\geq 1$  cm, low clinical suspicion for cancer.

Radiologic Procedure	Rating	Comments	RRL*
CT chest without IV contrast	8	To detect occult calcifications, fat, bronchus sign, etc.	☼☼☼
FDG-PET/CT whole body	8	If nodule is indeterminate on HRCT.	☼☼☼☼
Transthoracic needle biopsy	8	If nodule shows contrast enhancement or PET scan is positive.	Varies
CT chest with IV contrast	6	Probably not indicated if PET is performed.	☼☼☼
CT chest without and with IV contrast	6	Can look at washout.	☼☼☼
Watchful waiting with CT follow-up	4	Reasonable at short interval.	Varies
MRI chest without IV contrast	2	Limited data.	O
MRI chest without and with IV contrast	2	Limited data.	O
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

**Variant 2:** Solid nodule  $\geq 1$  cm, moderate to high clinical suspicion for cancer.

Radiologic Procedure	Rating	Comments	RRL*
CT chest without IV contrast	8	To detect occult calcifications, fat, bronchus sign, etc.	☼☼☼
FDG-PET/CT whole body	8	If nodule is indeterminate on HRCT.	☼☼☼☼
Transthoracic needle biopsy	8	If nodule shows contrast enhancement or PET scan is positive.	Varies
CT chest with IV contrast	6	Probably not indicated if PET is performed.	☼☼☼
CT chest without and with IV contrast	6	Can look at washout.	☼☼☼
Watchful waiting with CT follow-up	2		Varies
MRI chest without IV contrast	2	Limited data.	O
MRI chest without and with IV contrast	2	Limited data.	O
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

**Clinical Condition:** Radiographically Detected Solitary Pulmonary Nodule

**Variant 3:** Solid nodule <1 cm, low clinical suspicion for cancer.

Radiologic Procedure	Rating	Comments	RRL*
Watchful waiting with CT follow-up	8		Varies
CT chest without IV contrast	7		☼☼☼
CT chest without and with IV contrast	5	Depends on size (washout study).	☼☼☼
CT chest with IV contrast	3		☼☼☼
FDG-PET/CT whole body	3		☼☼☼☼
Transthoracic needle biopsy	2		Varies
MRI chest without IV contrast	2	Limited data.	O
MRI chest without and with IV contrast	2	Limited data.	O
<b><u>Rating Scale:</u></b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

**Variant 4:** Solid nodule <1 cm, moderate to high clinical suspicion for cancer.

Radiologic Procedure	Rating	Comments	RRL*
CT chest without IV contrast	8		☼☼☼
Transthoracic needle biopsy	6		Varies
Watchful waiting with CT follow-up	5		Varies
CT chest without and with IV contrast	5	Depends on size (washout study).	☼☼☼
CT chest with IV contrast	4		☼☼☼
FDG-PET/CT whole body	2		☼☼☼☼
MRI chest without IV contrast	2	Limited data.	O
MRI chest without and with IV contrast	2	Limited data.	O
<b><u>Rating Scale:</u></b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

## RADIOGRAPHICALLY DETECTED SOLITARY PULMONARY NODULE

Expert Panel on Thoracic Imaging: Jeffrey P. Kanne, MD<sup>1</sup>; Leif E. Jensen, MD, MPH<sup>2</sup>; Tan-Lucien H. Mohammed, MD<sup>3</sup>; Jacobo Kirsch, MD<sup>4</sup>; Judith K. Amorosa, MD<sup>5</sup>; Kathleen Brown, MD<sup>6</sup>; Jonathan H. Chung, MD<sup>7</sup>; Debra Sue Dyer, MD<sup>8</sup>; Mark E. Ginsburg, MD<sup>9</sup>; Darel E. Heitkamp, MD<sup>10</sup>; Ella A. Kazerooni, MD<sup>11</sup>; Loren H. Ketai, MD<sup>12</sup>; J. Anthony Parker, MD, PhD<sup>13</sup>; James G. Ravenel, MD<sup>14</sup>; Anthony G. Saleh, MD<sup>15</sup>; Rakesh D. Shah, MD.<sup>16</sup>

### **Summary of Literature Review**

#### **Introduction/Background**

The solitary pulmonary nodule is defined as a rounded opacity  $\leq 3$  cm in diameter surrounded by lung parenchyma [1]. There should be no associated abnormality, including atelectasis or hilar lymphadenopathy. This definition is based on information obtained from the chest radiograph. On computed tomography (CT), nodules are described as being solid, semisolid (mixed attenuation), or ground-glass attenuation. Pure ground-glass attenuation nodules are areas of increased lung attenuation through which normal structures such as vessels or septa remain discernible.

The incidence of solitary nodules detected by chest radiography was previously estimated to be approximately 150,000 per year in the United States [2]. However, this figure did not include the multitude of smaller nodules detected with CT. When these are included, the incidence of pulmonary nodules in the general population dramatically increases, though precise estimates are not available. Although what constitutes a small nodule is not formally established, nodules with diameters  $< 1$  cm are generally considered small. As with radiographically detected nodules, the primary aim in evaluating these smaller nodules is the ability to confirm or exclude malignancy.

Although pulmonary nodules have been studied for decades, there are few reliable characteristics to distinguish benign from malignant nodules. The only findings sufficient to preclude further evaluation are a benign pattern of calcification or stability of nodule size for over 2 years for solid pulmonary nodules. Both of these criteria have been known since the early 1950s. Recently, the radiologic-pathologic correlation of pure ground-glass attenuation nodules and mixed attenuation nodules with the histologic spectrum of pulmonary adenocarcinoma has been described [3]. While not all ground-glass attenuation nodules are malignant, they are more likely to be multiple and may demonstrate an indolent growth pattern, rendering 2-year stability inadequate to establish benignity. The likelihood of malignancy increases with nodule size, which may influence management strategy. Other nodule features such as shape, edge characteristics, cavitation, and location have not yet been found to be accurate clues for distinguishing benign from malignant nodules [4]. As a result, the majority of nodules are indeterminate.

#### **Overview of Diagnostic Tests**

A host of diagnostic tests are available to evaluate patients with solitary pulmonary nodules. It should be noted that for all of these tests, the accuracy tends to decrease with smaller nodule size. Diagnostic tests range from noninvasive decision-theoretic approaches to major surgery. It is often the role of the radiologist to suggest an appropriate management strategy.

Theoretic approaches for decision-making include the use of Bayes theorem, logistic regression models, and neural network analysis [5-8]. These approaches are useful primarily in estimating the probability of malignancy for a particular nodule. Information from the radiologic appearance of the nodule such as size, shape, and edge characteristics can be combined with clinical risk information such as age and smoking history to produce an

---

<sup>1</sup>Principal Author, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. <sup>2</sup>Research Author, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. <sup>3</sup>Panel Chair, Cleveland Clinic Foundation, Cleveland, Ohio. <sup>4</sup>Panel Vice-chair, Cleveland Clinic, Weston, Florida. <sup>5</sup>Robert Wood Johnson Medical School, New Brunswick, New Jersey. <sup>6</sup>Ronald Regan UCLA Medical Center, Los Angeles, California. <sup>7</sup>National Jewish Health, Denver, Colorado. <sup>8</sup>National Jewish Health, Denver, Colorado. <sup>9</sup>Columbia University, New York, New York, Society of Thoracic Surgeons. <sup>10</sup>Indiana University, Indianapolis, Indiana. <sup>11</sup>University of Michigan Medical Center, Ann Arbor, Michigan. <sup>12</sup>University of New Mexico, Albuquerque, New Mexico. <sup>13</sup>Beth Israel Deaconess Medical Center, Boston, Massachusetts, Society of Nuclear Medicine. <sup>14</sup>Medical University of South Carolina, Charleston, South Carolina. <sup>15</sup>New York Methodist Hospital, Brooklyn, New York, The American College of Chest Physicians. <sup>16</sup>North Shore University Hospital, Manhasset, New York.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document.

Reprint requests to: [publications@acr.org](mailto:publications@acr.org)

overall probability for malignancy. If this probability can be set sufficiently low, strategies that include observing nodules for interval change can be advocated [9]. These estimates can be combined with subsequent imaging information to further define the probability of malignancy and guide additional steps in the diagnostic workup [10].

Extensive work is now being done using advanced image processing techniques to further evaluate nodule attributes and change over time. One area of investigation includes the ability to use 3-dimensional nodule characteristics. Volumetric analysis measures growth of nodules in short time intervals, allowing for assessment of doubling time, a biologic measure of tumor aggressiveness. Changes in nodule morphology and attenuation are also being assessed [11]. Factors that affect the reproducibility of nodule volume measurement on CT include nodule size at detection, examination technique, nodule relationship to adjacent structures, underlying lung disease, and patient factors such as phase of respiration and cardiac motion [12].

Computed-aided detection (CAD) systems have been developed for lung nodule detection on CT. CAD has the potential to improve radiologists' diagnostic confidence in detection and accuracy in distinguishing small benign nodules from malignant ones on high-resolution CT (HRCT) [13-15]. At this point, studies have shown that CAD information can be helpful in clinical practice by providing radiologists a "second opinion" [16].

### **Computed Tomography**

Contrast-enhanced CT of solitary pulmonary nodules has also been used to distinguish benign from malignant nodules. Results from a large multicenter study found that contrast-enhanced CT has a sensitivity of 98% and a specificity of 58% when using a cutoff of 15 Hounsfield units for enhancement. This led the authors to conclude that absence of enhancement is a strong predictor of benignity [17]. An analysis of combined wash-in and washout characteristics at dynamic contrast-enhanced multidetector CT showed 92% accuracy for distinguishing benign from malignant nodules [18]. The extent of enhancement reflects underlying nodule angiogenesis [19]. Limitations of the technique relate to its nonspecific nature for inflammatory disease and measurement error in evaluation of small nodules. Dual-energy CT imaging has also been used in several studies to evaluate nodules with similar diagnostic accuracy [20,21]. Through postprocessing techniques, contrast-enhanced and virtual-noncontrast images are generated from a single acquisition, which may reduce patient radiation dose.

### **Magnetic Resonance Imaging**

Use of magnetic resonance imaging (MRI) in evaluation of pulmonary nodules has thus far been limited. Faster imaging sequences and techniques to mitigate artifact have allowed for detection of smaller nodules (6-10 mm) with sensitivity near 95% [22]. For nodules >1 cm, contrast-enhanced dynamic MRI has shown to be comparable to CT for distinguishing benign from malignant nodules with a sensitivity of 96%, specificity of 88%, and accuracy of 92% [23-25]. The possibility of a nonionizing assessment method for nodules is attractive, especially for younger patients. However, further research and validation are required to define a place for MR in clinical practice.

### **Positron Emission Tomography**

Positron emission tomography (PET) using fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG) has assumed a major role in the evaluation of patients with solitary pulmonary nodules. This technique relies on measuring glucose metabolism, which has been shown to be different between benign and malignant nodules. Many studies have demonstrated the accuracy of FDG-PET in evaluating solitary pulmonary nodules [26]. The sensitivity and specificity for this technique, as reported in the literature, have ranged from 83%-97% and from 69%-100%, respectively. FDG-PET has a higher specificity and only slightly reduced sensitivity compared to nodule-enhancement CT [27]. Limitations of PET scanning include its inability to accurately characterize certain types of lesions, including low-grade adenocarcinoma and typical carcinoid tumors. It is also limited in its ability to characterize nodules <1 cm in diameter and it may give false-positive results in patients with active infections and inflammatory diseases.

### **Other Diagnostic Tests**

The aggressive nature of lung cancer often compels the diagnostic evaluation to be near certainty, and consequently tests that provide pathologic material are quite useful. Currently, such diagnostic tests include transthoracic needle biopsy (TNB), bronchoscopy, video-assisted thoracoscopic surgery (VATS), and thoracotomy. The relative roles of these procedures are not well defined in existing literature, perhaps because of the lack of a defined sensitivity and specificity for the semi-invasive tests. Both TNB [28-31] and bronchoscopy

[32] are highly dependent on nodule size and location and on the skill of the person performing the procedure. In general, TNB has a higher sensitivity and specificity than bronchoscopy, and therefore it is usually a more appropriate test in diagnosing solitary nodules. CT fluoroscopy-guided lung biopsy using an automated cutting needle provides a high degree of diagnostic accuracy, allows for the specific characterization of lung nodules, and can be performed safely with a sensitivity of 95.1%, specificity of 100%, and accuracy of 96.2% [33]. The role of TNB relative to the surgical approach depends primarily on the ability to make a benign diagnosis. If the only role of TNB is to confirm malignancy, then it only adds to the cost of the overall workup, although there can be some use in confirming malignancy before surgery, such as diagnosing small-cell carcinoma. The diagnosis of benign disease using TNB is generally divided into three broad categories: specific benign diagnosis, nonspecific benign diagnosis, and nondiagnostic biopsy.

Recent reports suggest that the number of specific benign diagnoses can be increased using core needles, although this occurs at the cost of increasing complication rates when large-caliber needles are used. In general, for benign nonspecific and nondiagnostic studies, repeat biopsy or resection is necessary [34]. Compared to thoracotomy, VATS offers the benefit of lower perioperative morbidity and decreased length of hospital stay. VATS is most successful for peripheral lesions and some central lesions in the lower lobe, and it is the surgical method of choice for diagnosis and resection of pulmonary nodules. If the nodules are too small or located too deeply to be detected thoroscopically, preoperative CT-guided placement of a pulmonary nodule-marker system like methylene blue or wires is a safe and accurate method of localizing pulmonary nodules at thoracoscopy [35,36].

Much of the information on which guidelines are based for management of small nodules is derived from lung cancer screening. Based on a retrospective review of 2,897 baseline screening scans, initial recommendations for noncalcified nodules measuring <5 mm were to have a follow-up scan in 1 year [37]. Management recommendations for small nodules were revised by the Fleischner Society in 2005, using separate algorithms for high- and low-risk patients [38]. Subsequently, The American College of Chest Physicians published a set of 29 recommendations for the evaluation and management of small nodules, which stress inclusion of patient preference in management decisions [39].

### **Summary**

- In view of the variety of diagnostic tests available and the variable accuracy of the different diagnostic techniques such as FDG-PET and TNB, no single algorithm for workup is generally accepted.
- Practices vary from institution to institution, likely because of the varying prevalence of lung disease in different parts of the country, varying skill levels of operators, and varying availability of equipment.

### **Relative Radiation Level Information**

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, both because of organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared to those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria® [Radiation Dose Assessment Introduction](#) document.

Relative Radiation Level Designations		
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
○	0 mSv	0 mSv
⊕	<0.1 mSv	<0.03 mSv
⊕⊕	0.1-1 mSv	0.03-0.3 mSv
⊕⊕⊕	1-10 mSv	0.3-3 mSv
⊕⊕⊕⊕	10-30 mSv	3-10 mSv
⊕⊕⊕⊕⊕	30-100 mSv	10-30 mSv

\*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “Varies”.

### Supporting Documents

For additional information on the Appropriateness Criteria methodology and other supporting documents go to [www.acr.org/ac](http://www.acr.org/ac).

### References

- Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. *Radiology*. 2008;246(3):697-722.
- Lillington GA. Disease-a-Month. 37th ed. St Louis, Mo: Mosby-Year Book; 1991:271-318.
- Godoy MC, Naidich DP. Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. *Radiology*. 2009;253(3):606-622.
- Brandman S, Ko JP. Pulmonary nodule detection, characterization, and management with multidetector computed tomography. *J Thorac Imaging*. 2011;26(2):90-105.
- Gurney JW. Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part I. Theory. *Radiology*. 1993;186(2):405-413.
- Henschke CI, Yankelevitz DF, Mateescu I, Brettle DW, Rainey TG, Weingard FS. Neural networks for the analysis of small pulmonary nodules. *Clin Imaging*. 1997;21(6):390-399.
- Nakamura K, Yoshida H, Engelmann R, et al. Computerized analysis of the likelihood of malignancy in solitary pulmonary nodules with use of artificial neural networks. *Radiology*. 2000;214(3):823-830.
- Swensen SJ, Silverstein MD, Ilstrup DM, Schleck CD, Edell ES. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. *Arch Intern Med*. 1997;157(8):849-855.
- Truong MT, Sabloff BS, Ko JP. Multidetector CT of solitary pulmonary nodules. *Radiol Clin North Am*. 2010;48(1):141-155.
- Matsuki Y, Nakamura K, Watanabe H, et al. Usefulness of an artificial neural network for differentiating benign from malignant pulmonary nodules on high-resolution CT: evaluation with receiver operating characteristic analysis. *AJR Am J Roentgenol*. 2002;178(3):657-663.
- de Hoop B, Gietema H, van de Vorst S, Murphy K, van Klaveren RJ, Prokop M. Pulmonary ground-glass nodules: increase in mass as an early indicator of growth. *Radiology*. 2010;255(1):199-206.
- Kostis WJ, Yankelevitz DF, Reeves AP, Fluture SC, Henschke CI. Small pulmonary nodules: reproducibility of three-dimensional volumetric measurement and estimation of time to follow-up CT. *Radiology*. 2004;231(2):446-452.
- Brown MS, Goldin JG, Rogers S, et al. Computer-aided lung nodule detection in CT: results of large-scale observer test. *Acad Radiol*. 2005;12(6):681-686.
- Li F, Aoyama M, Shiraishi J, et al. Radiologists' performance for differentiating benign from malignant lung nodules on high-resolution CT using computer-estimated likelihood of malignancy. *AJR Am J Roentgenol*. 2004;183(5):1209-1215.

15. Nietert PJ, Ravenel JG, Taylor KK, Silvestri GA. Influence of nodule detection software on radiologists' confidence in identifying pulmonary nodules with computed tomography. *J Thorac Imaging*. 2011;26(1):48-53.
16. White CS, Pugatch R, Koonce T, Rust SW, Dharaiya E. Lung nodule CAD software as a second reader: a multicenter study. *Acad Radiol*. 2008;15(3):326-333.
17. Swensen SJ, Viggiano RW, Midthun DE, et al. Lung nodule enhancement at CT: multicenter study. *Radiology*. 2000;214(1):73-80.
18. Jeong YJ, Lee KS, Jeong SY, et al. Solitary pulmonary nodule: characterization with combined wash-in and washout features at dynamic multi-detector row CT. *Radiology*. 2005;237(2):675-683.
19. Yi CA, Lee KS, Kim EA, et al. Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. *Radiology*. 2004;233(1):191-199.
20. Chae EJ, Song JW, Seo JB, Krauss B, Jang YM, Song KS. Clinical utility of dual-energy CT in the evaluation of solitary pulmonary nodules: initial experience. *Radiology*. 2008;249(2):671-681.
21. Kang MJ, Park CM, Lee CH, Goo JM, Lee HJ. Dual-energy CT: clinical applications in various pulmonary diseases. *Radiographics*. 2010;30(3):685-698.
22. Schroeder T, Ruehm SG, Debatin JF, Ladd ME, Barkhausen J, Goehde SC. Detection of pulmonary nodules using a 2D HASTE MR sequence: comparison with MDCT. *AJR Am J Roentgenol*. 2005;185(4):979-984.
23. Kim JH, Kim HJ, Lee KH, Kim KH, Lee HL. Solitary pulmonary nodules: a comparative study evaluated with contrast-enhanced dynamic MR imaging and CT. *J Comput Assist Tomogr*. 2004;28(6):766-775.
24. Schaefer JF, Vollmar J, Schick F, et al. Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging-perfusion differences in malignant and benign lesions. *Radiology*. 2004;232(2):544-553.
25. Kono R, Fujimoto K, Terasaki H, et al. Dynamic MRI of solitary pulmonary nodules: comparison of enhancement patterns of malignant and benign small peripheral lung lesions. *AJR Am J Roentgenol*. 2007;188(1):26-36.
26. Mavi A, Lakhani P, Zhuang H, Gupta NC, Alavi A. Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. *Radiol Clin North Am*. 2005;43(1):1-21, ix.
27. Christensen JA, Nathan MA, Mullan BP, Hartman TE, Swensen SJ, Lowe VJ. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT. *AJR Am J Roentgenol*. 2006;187(5):1361-1367.
28. Geraghty PR, Kee ST, McFarlane G, Razavi MK, Sze DY, Dake MD. CT-guided transthoracic needle aspiration biopsy of pulmonary nodules: needle size and pneumothorax rate. *Radiology*. 2003;229(2):475-481.
29. Wallace MJ, Krishnamurthy S, Broemeling LD, et al. CT-guided percutaneous fine-needle aspiration biopsy of small (< or =1-cm) pulmonary lesions. *Radiology*. 2002;225(3):823-828.
30. Westcott JL. Needle biopsy of the chest. In: Tavares J, Ferruci J, eds. *Imaging- Diagnosis- Intervention*. Philadelphia, Pa.: Lippincott; 1993:1-3.
31. Yankelevitz DF, Wisnivesky JP, Henschke CI. Comparison of biopsy techniques in assessment of solitary pulmonary nodules. *Semin Ultrasound CT MR*. 2000;21(2):139-148.
32. Baaklini WA, Reinoso MA, Gorin AB, Sharafkaneh A, Manian P. Diagnostic yield of fiberoptic bronchoscopy in evaluating solitary pulmonary nodules. *Chest*. 2000;117(4):1049-1054.
33. Yamagami T, Iida S, Kato T, et al. Usefulness of new automated cutting needle for tissue-core biopsy of lung nodules under CT fluoroscopic guidance. *Chest*. 2003;124(1):147-154.
34. Savage C, Walser EM, Schnadig V, Woodside KJ, Ustuner E, Zwischenberger JB. Transthoracic image-guided biopsy of lung nodules: when is benign really benign? *J Vasc Interv Radiol*. 2004;15(2 Pt 1):161-164.
35. Dendo S, Kanazawa S, Ando A, et al. Preoperative localization of small pulmonary lesions with a short hook wire and suture system: experience with 168 procedures. *Radiology*. 2002;225(2):511-518.
36. Hanninen EL, Langrehr J, Raakow R, et al. Computed tomography-guided pulmonary nodule localization before thoracoscopic resection. *Acta Radiol*. 2004;45(3):284-288.
37. Henschke CI, Yankelevitz DF, Naidich DP, et al. CT screening for lung cancer: suspiciousness of nodules according to size on baseline scans. *Radiology*. 2004;231(1):164-168.
38. MacMahon H, Austin JH, Gamsu G, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. *Radiology*. 2005;237(2):395-400.

39. Gould MK, Fletcher J, Iannettoni MD, et al. Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest*. 2007;132(3 Suppl):108S-130S.

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.